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Acyclic nucleoside phosphonates are novel nucleotide analogs in which a phosphonate group is linked to the alkyl side chain of various purines and pyrimidines (10, 16, (17) (18) (19) . The purine derivatives include (S)-9-(3-hydroxy-2-phosphonomethoxypropyl)adenine [(S)-HPMPA], an agent with a broad-spectrum anti-DNA virus activity (10, 14, 16, 19) ; 9-(2-phosphonomethoxyethyl)adenine (PMEA), which shows both antiherpesvirus and antiretrovirus activity (4, 5, 10, 13, 16, 19, 21, 23) ; and 9-(3-fluoro-2-phosphonomethoxypropyl)adenine (FPMPA), which has antiretrovirus activity (2, 7) (Fig.  1 ). The 9-(3-hydroxy-2-phosphonomethoxypropyl) (HPMP) and 9-(3-fluoro-2-phosphonomethoxypropyl) (FPMP) derivatives contain an asymmetric carbon atom in the aliphatic side chain, which results in both (S)-and (R)-enantiomers.
For FPMPA and related compounds, antiretroviral studies in vitro and in vivo have so far been carried out with the racemic mixtures (2) . We have now synthesized the individual (S)-and (R)-enantiomers of the HPMP and FPMP derivatives and also of the novel series of 9-(2-phosphonomethoxypropyl) (PMP) derivatives (Fig. 1 ). Of these compounds, the (R)-enantiomer of PMP 2,6-diaminopurine (PM-PDAP) emerged as the most potent and selective inhibitor of human immunodeficiency virus (HIV) and Moloney murine sarcoma virus (MSV).
MATERIALS AND METHODS
Test compounds. The synthesis of the (S)-and (R)-enantiomers of HPMP, FPMP and PMP purine (i.e., adenine, DAP, 2-aminopurine [MAP], and guanine [G]) derivatives will be reported in separate articles. For the synthesis of the individual enantiomers in the (S)-HPMP, (S)-FPMP, and (R)-FPMP series, synthons prepared by enantiospecific reactions which started from natural carbohydrates of a defined chirality were used. These synthons were used for alkylation of suitable heterocyclic bases. All of these procedures were essentially insensitive to any racemization. The synthesis of the (R)-HPMP and (R)-and (S)-PMP enantiomers was based on chiral synthons which were obtained from commercially available chiral glycidol derivatives or lactic acid esters with known optical purity. The transformation took place apart from the chiral center. The enantiomeric purity of the products in the HPMP and FPMP series was verified by a high-performance liquid chromatography technique (4 mM copper sulfate and 4 mM L-phenylalanine, pH 3.1). The (S)-HPMP, (S)-FPMP, and (R)-FPMP enantiomers were >98% enantiomerically pure (sensitivity limit), while the optical purity of the (R)-HPMP derivatives (purity, >95%) corresponded to the optical purity of the commercially available starting material. We were unable to detect any mutual contaminants in the pairs of enantiomeric PMP derivatives. PMEA and PMEDAP were synthesized by using a previously published procedure (18) . The the adenine derivatives (HPMPA, FPMPA, and PMPA) are depicted in Fig. 1 . The configuration of C-2 of (S)-HPMPA and (S)-FPMPA is identical to that of (R)-PMPA.
Viruses. The origins of MSV, HIV type 1 (HIV-1; strain HTLV-IIIB), HIV-2 (strain LAV-2), herpes simplex virus type 1 (HSV-1; strains KOS, F, and McIntyre), HSV-2 (strains G, 196, and Lyons), cytomegalovirus (CMV; strain AD-169), varicella-zoster virus (VZV; strains OKA and YS) and vaccinia virus (VV) have been described previously (1, 5, 9, 12, 15, 24, 26) .
In vitro antiviral assays. As described previously (1, 5, 12, 19) , antiviral activity determinations for HSV-1, HSV-2, and VV were based on the microscopic examination of virusinduced cytopathicity in human embryonic skin-muscle (E6SM) cells at 3 days postinfection. HSV-1, HSV-2, and VV were added at 100 CCID50 to the cell cultures (1 CCID50 being the virus dose that is able to infect 50% of the cell cultures). Anti-VZV and anti-CMV activity was evaluated by plaque formation in human embryonic lung (HEL) cells at day 7 postinfection. VZV and CMV were added at 20 and 100 PFU per well, respectively, to the cell cultures in 96-well microtiter plates. The activity against HIV-1-and HIV-2-induced cytopathicity was examined in MT-4 cells at day 5 postinfection and based on the determination of cell viability by trypan blue dye staining. HIV-1 and HIV-2 were added at 100 CCID50 to the cell cultures. The inhibitory effect of the test compounds on MSV-induced transformation of murine embryo fibroblast C3H/3T3 cell cultures was examined microscopically at day 6 postinfection. MSV was added at 75 focus-forming units to the cell cultures.
The inhibition of the expression of HIV-1 (IIIB)-specific antigens in MT-4 cells was measured by an indirect immunofluorescence-flow cytofluorographic method (25) by using a high-titer polyclonal antibody (derived from a patient with AIDS-related complex [diluted 1/500 in phosphate-buffered saline]) and fluorescein isothiocyanate-conjugated F(ab')2 fragments of rabbit-anti-human immunoglobulin antibody (Prosan, Ghent, Belgium) at day 4 after infection.
Anti-MSV activity in vivo. The inhibitory effects of the compounds on the initiation of MSV-induced tumor formation and survival of MSV-inoculated mice were evaluated as previously described (2, 4 its (S)-enantiomer against all of the DNA viruses tested, (R)-HPMPDAP proved equally active against VZV but 20-fold less effective against CMV than (S)-HPMPDAP (Table  1) . Also, (S)-HPMPG was 70-fold more active against VV than (R)-HPMPG, whereas (R)-HPMPG was at least as potent in inhibiting HSV-2 and CMV replication as (S)-HPMPG. As a rule, the (R)-HPMPG enantiomer was more cytotoxic than its corresponding adenine and DAP derivatives, irrespective of the cell line used; (R)-HPMPG was also more toxic than (S)-HPMPG (Tables 1 and 2 without being toxic at a concentration of 300 ,uM ( Table 2) . Most of the FPMP and PMP derivatives showed marked anti-HIV activity in vitro. In general, HIV-1 and HIV-2 did not differ in their sensitivity to these compounds when tested in either MT-4 cells (Table 2) or CEM cells (data not shown). The (S)-enantiomer of FPMPA was much more active against HIV than its (R)-enantiomer. For PMPA, the (R)-enantiomer was much more effective than the (S)-enantiomer. However, it should be pointed out that the difference in designation is purely arbitrary: the configuration at the C-2 atom of (S)-FPMPA is identical to that of (R)-PMPA, and, conversely, the configuration of (R)-FPMPA is identical to that of (S)-PMPA (Fig. 1) .
The (S)-and (R)-enantiomers of the FPMP and PMP derivatives of DAP and guanine did not show marked differences in their activity against HIV. However, (R)-PMPDAP proved at least 40-to 50-fold more inhibitory than the corresponding (S)-enantiomer (Table 2) . Recently, the racemic mixture of FPMPA has been evaluated in human peripheral blood lymphocyte cells and human monocytes/ macrophages in vitro and found to be equally inhibitory to
HIV-1 replication in these cells as in MT-4 or CEM cells (7).
Similar observations were made for the anti-MSV activity in C3H/3T3 cells as for the anti-HIV activity in MT-4 cells for all test compounds, except for the HPMP derivatives, which proved active against MSV but not HIV at subtoxic concentrations (Table 2) (Table 3) , and, even at a dose of 2 mg/kg, (R)-PMPDAP prevented tumor formation in 33% of the MSV-infected mice. At these doses, a marked percentage of long-term survivors (i.e., 93 and 47%, respectively) was observed. Neither (R)-PMPDAP, (R)-PMPA, nor (S)-FPMPA was toxic to the mice at the highest dose tested (50 mg/kg).
Efficacy of oral (R)-PMPDAP, PMEDAP, and PMEA against MSV-induced tumor formation. (R)-PMPDAP and PMEDAP were markedly effective in delaying MSV-induced tumor formation (Table 4 ). In addition, tumor growth in treated mice proceeded markedly slower than in control mice, and only 83% of mice developed a tumor within the 15-day observation period. In contrast, PMEA had no significant anti-MSV effect when administered orally at a dose of 100 mg/kg/day. It is intriguing that the (S)-and (R)-enantiomers of the DAP derivatives within the HPMP and FPMP series are endowed with more or less similar anti-HIV and anti-MSV activities in vitro, whereas within the PMP series, (R)-PMPDAP is by far superior (20-to 50-fold) to (S)-PMPDAP in its antiretroviral action in vitro. Metabolism studies as well as kinetic investigations of the interaction of these test compounds with their target enzyme (RT) may clarify this issue.
Interestingly, under the experimental conditions that easily permit the selection of HIV-1 strains that are resistant to the HIV-1-specific inhibitors TIBO, nevirapine, pyridinone, and TSAO (3), we were unable to isolate HIV-1 strains resistant to PMEA, (R)-PMPDAP, and (S)-FPMPA (data not shown). On the other hand, TIBO-, nevirapine-, pyridinone-, and TSAO-resistant HIV-1 strains remained fully sensitive to the acyclic nucleoside phosphonates (3, 6, 8) . These observations suggest that the interaction of the acyclic nucleoside phosphonate derivatives with HIV RT clearly differs from that of the other HIV-1-specific RT inhibitors. It also implies that HIV-1 infections that have become resistant to the action of the HIV-1-specific RT inhibitors can still be successfully treated with acyclic nucleoside phosphonates.
In conclusion, (R)-PMPDAP, (R)-PMPA, and (S)-FPMPA emerged as very potent and selective antiretrovirus agents in vitro and in vivo. In particular, (R)-PMPDAP exhibited the most pronounced antiretrovirus activity in vitro and in vivo and should be considered a prime candidate compound for further development for the treatment of retroviral diseases (e.g., AIDS).
